Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01801046 · ClinicalTrials.gov registry record · Phase 1

Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

A Phase 1 study, sponsored by University of Southern California.

Terminated
Registry status
Phase 1
Development phase
10
Enrollment target

NCT01801046: Clinical Trial Phase 1 study, sponsored by University of Southern California.

NCT01801046 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01801046, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.

TERMINATED
Registry status
Phase 1
Development phase
10 participants
Enrollment target

Study Summary

This phase I trial studies the side effects of donor stem cell transplant in treating patients with high risk acute myeloid leukemia. Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect)

Interventions

  • OTHER laboratory biomarker analysis
  • PROCEDURE peripheral blood stem cell transplantation
  • DRUG cytarabine
  • DRUG mitoxantrone hydrochloride

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2013-03-06
Est. Completion 2017-08-20
Phase Phase 1
University of Southern California

617 total trials

Why NCT01801046 stopped before completion

NCT01801046 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT01801046 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01801046 about?

NCT01801046 is a clinical study titled "Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia". This phase I trial studies the side effects of donor stem cell transplant in treating patients with high risk acute myeloid leukemia. Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune sys...

What is the current status of trial NCT01801046?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2013-03-06. Estimated completion is 2017-08-20.

What interventions are being tested in trial NCT01801046?

The interventions under investigation include: laboratory biomarker analysis (OTHER), peripheral blood stem cell transplantation (PROCEDURE), cytarabine (DRUG), mitoxantrone hydrochloride (DRUG).

Who is sponsoring clinical trial NCT01801046?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01801046's enrollment target sits among peer trials

10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01801046, the US trial registry maintained by the National Library of Medicine. NCT01801046 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.